Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

NCT02601248 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Theliatinib

Sponsor

Hutchison Medipharma Limited